
Symphony Vida
About Symphony Vida
Symphony Vida is a Healthcare company based in Rockville (United States), and was acquired by Mateon Therapeutics in July 2009. Therapeutics for cancer and eye diseases are developed. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Therapeutics targeting cancer and neovascular eye diseases are developed by Symphony Vida, a biotechnology firm located in Rockville, United States. Operations center on advancing treatments for multiple cancer types and ocular conditions. A collaboration with Oxigene has been pursued to support drug development efforts in oncology and ophthalmology, with activities conducted primarily in the pharmaceutical sector.
- Headquarters Rockville, United States
- Stage Acquired
- SectorsHealthcare
- Website symphonyvida.com
- Acquired by Mateon Therapeutics (Jul 2009)
- Investors
- Acquired byMateon Therapeutics
(Jul 2009)
Investors in Symphony Vida
Symphony Vida has secured backing from 1 investor. Prominent investors backing the company include Mateon Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Vascular targeted therapies are developed for rare diseases and cancers. | 1996 | mateon.com | San Francisco, United States |
Investor details for Symphony Vida
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Competitors of Symphony Vida
Symphony Vida has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Symphony Vida
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Symphony Vida (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Symphony Vida
Symphony Vida is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Therapeutics targeting cancer and neovascular eye diseases are developed by Symphony Vida, a biotechnology firm located in Rockville, United States. Operations center on advancing treatments for multiple cancer types and ocular conditions. A collaboration with Oxigene has been pursued to support drug development efforts in oncology and ophthalmology, with activities conducted primarily in the pharmaceutical sector.
Symphony Vida's top competitors include C4 Therapeutics, Erasca and MiRagen.
Symphony Vida has 1 investor. Key investors include Mateon Therapeutics.
Yes. Symphony Vida was acquired by Mateon Therapeutics in July 2009.